NCT05140382 - AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 15, 2021

Primary Completion Date

August 25, 2023

Study Completion Date

February 16, 2024

Conditions

Relapsed/Refractory Peripheral T-cell LymphomaRelapsed/Refractory Classical Hodgkins Lymphoma

Interventions

DRUG

AZD4573

AZD4573 will be given intravenously

Trial Locations (27)

100

Research Site, Taipei

3000

Research Site, Melbourne

3168

Research Site, Clayton

6009

Research Site, Nedlands

25000

Research Site, Besançon

34295

Research Site, Montpellier

40138

Research Site, Bologna

40447

Research Site, Taichung

59037

Research Site, Lille

63003

Research Site, Clermont-Ferrand

70403

Research Site, Tainan City

77030

Research Site, Houston

80131

Research Site, Napoli

83301

Research Site, Kaohsiung City

84112

Research Site, Salt Lake City

91010

Research Site, Duarte

94010

Research Site, Créteil

98104

Research Site, Seattle

02215

Research Site, Boston

07601

Research Site, Hackensack

03080

Research Site, Seoul

03722

Research Site, Seoul

05505

Research Site, Seoul

06351

Research Site, Seoul

221 85

Research Site, Lund

0X3 7LJ

Research Site, Headington

NW1 2PG

Research Site, London